Cancer cell Cytotoxicities of 1-(4-substitutedbenzoyl)-4-(4-chlorobenzhydryl)piperazine derivatives

International Journal of Molecular Sciences

Volumn 13, Issue 7, 2012, Pages 8071-8085

  Yarim, Mine ^a   Koksal, Meric ^a   Durmaz, Irem ^b   Atalay, Rengul ^b  

^a YEDITEPE UNIVERSITY   (Turkey)

^b BILKENT UNIVERSITY   (Turkey)

Author keywords

1 (4 chlorobenzhydryl)piperazine derivatives; Benzoyl chlorides; Cancer; Cell proliferation; Cytotoxicity

Indexed keywords

1 (2,4 DIFLUOROBENZOYL) 4 (4 CHLOROBENZHYDRYL)PIPERAZINE; 1 (4 BROMOBENZOYL) 4 (4 CHLOROBENZHYDRYL)PIPERAZINE; 1 (4 CHLOROBENZOYL) 4 (4 CHLOROBENZHYDRYL)PIPERAZINE; 1 (4 FLUOROBENZOYL) 4 (4 CHLOROBENZHYDRYL)PIPERAZINE; 1 (4 METHOXYBENZOYL) 4 (4 CHLOROBENZHYDRYL)PIPERAZINE; 1 (4 NITROBENZOYL) 4 (4 CHLOROBENZHYDRYL)PIPERAZINE; 1 (4 PHENYLBENZOYL) 4 (4 CHLOROBENZHYDRYL)PIPERAZINE; 1 (4 SUBSITUTED BENZOYL) 4 (4 CHLOROBENZHYDRYL)PIPERAZINE DERIVATIVE; CAMPTOTHECIN; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; ENANTIOMER; ENDOMETRIUM CANCER; GROWTH INHIBITION; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; LIVER CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; STOMACH CANCER; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; IC50; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; PIPERAZINES;

EID: 84864377005     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13078071     Document Type: Article

References (33)

1. Sawyers, C. Targeted cancer therapy. Nature 2004, 432, 294-297.
2. Li, Q.; Xu, W. Novel anticancer targets and drug discovery in post genomic age. Curr. Med. Chem. Anticancer Agents 2005, 5, 53-55.
3. Mencher, S.K.; Wang, L.G. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin. Pharmacol. 2005, 5, 3-7.
4. Jimeno, A.; Hidalgo, M. Multitargeted therapy: Can promiscuity be praised in an era of political correctness? Crit. Rev. Oncol. Hematol. 2006, 59, 150-158.
5. Berkheij, M.; van der Sluis, L.; Sewing, C.J.; den Boer, D.; Terpstra, J.W.; Hiemstra, H.; Bakker, W.I.I.; van den Hoogenband, A.; van Haarseveen, J.H. Synthesis of 2-substituted piperazines via direct α-lithiation. Tetrahedron Lett. 2005, 46, 2369-2371.
6. Guo, C.C.; Tong, R.B.; Li, K.L. Chloroalkyl piperazine and nitrogen mustard porphyrins: Synthesis and anticancer activity. Bioorg. Med. Chem. 2004, 12, 2469-2475.
7. Gillet, R.; Jeannesson, P.; Sefraoui, H.; Arnould-GueArin, M.; Kirkiacharian, L.S.; Jardillier, J.C.; Pieri, F. Piperazine derivatives of butyric acid as differentiating agents in human leukemic cells. Cancer Chemother. Pharmaco. 1998, 41, 252-255.
8. Gabriel, F.E.; Gu, J.; Slater, L.M.; Hara, K.; Jacobs, J.W. Tumor apoptosis induced by epoxide-containing piperazines, a new class of anti-cancer agents. Cancer Chemother. Pharmacol. 2000, 45, 183-191.
9. Hulme, C.; Ma, L.; Romano, J.; Morisette, M. Novel applications of ethyl glyoxalate with the Ugi MCR. Tetrahedron Lett. 1999, 40, 5295-5299.
10. Upadhayaya, R.S.; Sinha, N.; Jain, S.; Kishore, N.; Chandra, R. Arora, S.K. Optically active antifungal azoles: Synthesis and antifungal activity of (2R,3S)-2-(2,4-difluorophenyl)-3-(5-[2-[4-aryl-piperazin-1-yl]-ethyl]-tetrazol-2-yl/1-yl)-1-[1,2,4]-triazol-1-yl-butan-2-ol. Bioorg. Med. Chem. 2004, 12, 2225-2238.
11. Choudhary, P.; Kumar, R.; Verma, K. Synthesis and antimicrobial activity of N-alkyl and N-aryl piperazine derivatives. Bioorg. Med. Chem. 2006, 14, 1819-1826.
12. Dorsey, B.D.; Levin, R.B.; McDaniel, S.L.; Vacca, J.P.; Guare, J.P.; Darke, P.L.; Zugay, J.A.; Emini, E.A.; Schleif, W.A. The design of a potent and orally bioavailable HIV protease inhibitor. J. Med. Chem. 1994, 37, 3443-3451.
13. Askin, D.; Eng, K.K.; Rossen, K.; Purick, R.M.; Wells, K.M.; Volante, R.P.; Reider, P.J. Highly diasteroselective reaction of a chiral, non-racemic amide enolate with (S)-glycidyl tosylate. synthesis of the orally active HIV-1 protease inhibitor L-735,524. Tetrahedron Lett. 1994, 35, 673-676.
14. Rosen, K.; Weissman, S.A.; Sager, J.; Reamer, R.A.; Askin, D.; Volante, R.P.; Reider, P.J. Asymmetric Hydrogenation of tetrahydropyrazines: Synthesis of (S)-piperazine 2-tert-butylcarboxamide, an intermediate in the preparation of the HIV protease inhibitor indinavir. Tetrahedron Lett. 1995, 36, 6419-6422.
15. EGYT. Pyridine Derivatives Having Antidepressant Activity. U.S. Patent 3,865,828, 11 February 1975.
16. Yoshida, M.; Maehara, Y.; Sugimachi, K. MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy. Clin. Cancer Res. 1999, 5, 4295-4300.
17. Matulenko, M.A.; Hakeem, A.A.; Kolasa, T.; Nakane, M.; Terranova, M.A.; Uchic, M.E.; Miller, L.N.; Chang, R.; Donnelly-Roberts, D.L.; Namovic, M.T.; et al. Synthesis and functional activity of (2-aryl-1-piperazinyl)-N-(3-methylphenyl)acetamides: Selective dopamine D4 receptor agonists. Bioorg. Med. Chem. 2004, 12, 3471-3483.
18. Glase, S.A.; Akunne, H.C.; Georgic, L.M.; Haffner, T.G.; Mackenzie, R.G.; Manley, P.J.; Pugsley, T.A.; Wise, L.D. Substituted [(4-phenylpiperazinyl)-methyl]benzamides: Selective dopamine D4 agonists. J. Med. Chem. 1997, 40, 1771-1772.
19. Perrone, R.; Berardi, F.; Colabufo, N.A.; Leopoldo, M.; Tortorella, V. A structure-affinity relationship study on derivatives of N-[2-[4-(4-chlorophenyl)piperazin-1-yl]ethyl]-3-methoxybenzamide, a high-affinity and selective D4 receptor ligand. J. Med. Chem. 2000, 43, 270-277.
20. Chern, J.H.; Shia, K.S.; Hsu, T.A.; Tai, C.L.; Lee, C.C.; Lee, Y.C.; Chang, C.S.; Tseng, S.N.; Shih, S.R. Design, synthesis, and structure-activity relationship of pyrazolo[3,4-d]pyrimidines: A novel class of potent enterovirus inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 2519-2525.
21. Kimura, M.; Masudaa, T.; Yamadaa, K.; Mitania, M.; Kubota, N.; Kawakatsua, N.; Kishii, K.; Inazub, M.; Kiuchic, Y.; Oguchid, K.; et al. Syntheses of novel diphenyl piperazine derivatives and their activities as inhibitors of dopamine uptake in the central nervous system. Bioorg. Med. Chem. 2003, 11, 1621-1630.
22. Kimura, M.; Masudaa, T.; Yamadaa, K.; Mitania, M.; Kubota, N.; Kawakatsua, N.; Kishii, K.; Inazu, M.; Kiuchi, Y.; Oguchi, K.; et al. Novel diphenylalkyl piperazine derivatives with high affinities for the dopamine transporter. Bioorg. Med. Chem. 2003, 11, 3953-3963.
23. Kimara, M.; Masuda, T.; Yamada, K. Antioxidative activities of novel diphenylalkyl piperazine derivatives with high affinities for the dopamine transporter. Bioorg. Med. Chem. Lett. 2004, 14, 4287-4290.
24. Amin, E.A.; Welsh, W.J. Three-dimensional quantitative structure-Activity relationship (3D-QSAR) models for a novel class of piperazine-based stromelysin-1 (MMP-3) inhibitors: Applying a "divide and conquer" strategy. J. Med. Chem. 2003, 44, 3849-3855.
25. Braybrooke, J.P.; O'Byrne, K.J.; Propper, D.J.; Blann, A.; Saunders, M.; Dobbs, N.; Han, C.; Woodhull, J.; Mitchell, K.; Crew, J.; et al. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin. Cancer Res. 2000, 6, 4697-4704.
26. Wilson, W.D.; Barton, H.J.; Tanious, F.A.; Kong, S.B.; Strekowski, L. The interaction with DNA of unfused aromatic systems containing terminal piperazino substituents: Intercalation and groove-binding. Biophys. Chem. 1990, 35, 227-243.
27. Sampson, J.J.; Donkor, I.O.; Huang, T.L.; Adunyah, S.E. Novel piperazine induces apoptosis in U937 cells. Int. J. Biochem. Mol. Biol. 2011, 2, 78-88.
28. Narendra Sharath Chandra, J.N.; Sadashiva, C.T.; Kavitha, C.V.; Rangappa, K.S. Synthesis and in vitro antimicrobial studies of medicinally important novel N-alkyl and N-sulfonyl derivatives of 1-[bis(4-fluorophenyl)-methyl]piperazine. Bioorg. Med. Chem. 2006, 14, 6621-6627.
29. Ananda Kumar, C.S.; Nanjuda Swamy, S.; Thimmegawda, N.R.; Benaka Prasad, S.B.; Yip, G.W.; Rangappa, K.S. Synthesis and evaluation of 1-benzhydryl-sulfonyl-piperazine derivatives as inhibitors of MDA-MB-231 human breast cancer cell proliferation. Med. Chem. Res. 2007, 16, 179-187.
30. Ananda Kumar, C.S.; Benaka Prasad, S.B.; Viyana, K.; Chandrappa, S.; Thimmegawda, R.; Sunil Kumar, Y.C.; Sanjay, S.; Rangappa, K.S. Synthesis and in vitro antiproliferative activity of novel 1-benzhydrylpiperazine derivatives against human cancer cell lines. Eur. J. Med. Chem. 2009, 44, 1223-1229.
31. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bokesch, H.; Kenney, S.; Boyd, M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer. Inst. 1990, 4, 1107-1112.
32. Kirstein, S.L.; Atienza, J.M.; Xi, B.; Zhu, J.; Yu, N.; Wang, X.; Xu, X.; Abassi, Y.A. Live cell quality control and utility of real-time cell electronic sensing for assay development. Assay Drug Dev. Technol. 2006, 4, 545-553.
33. Buontempo, F.; Ersahin, T.; Missiroli, S.; Senturk, S.; Etro, D.; Ozturk, M.; Capitani, S.; Cetin-Atalay, R.; Neri, M.L. Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status. Invest. New Drugs 2010, doi:10.1007/s10637-010-9486-3.